MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
32.84
-0.37
-1.11%
After Hours: 32.84 0 0.00% 17:40 12/18 EST
OPEN
33.31
PREV CLOSE
33.21
HIGH
34.17
LOW
32.64
VOLUME
1.48M
TURNOVER
--
52 WEEK HIGH
46.75
52 WEEK LOW
25.81
MARKET CAP
3.17B
P/E (TTM)
-5.5302
1D
5D
1M
3M
1Y
5Y
1D
Wells Fargo Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
TipRanks · 10h ago
Evercore ISI Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
TipRanks · 13h ago
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 2d ago
Weekly Report: what happened at RARE last week (1208-1212)?
Weekly Report · 3d ago
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Seeking Alpha · 3d ago
Ultragenyx CFO Makes Significant Stock Sale!
TipRanks · 6d ago
How Attractive Is Ultragenyx Pharmaceutical After Recent Rare Disease Pipeline Progress?
Simply Wall St · 12/11 19:40
Ultragenyx CFO Howard Horn Reports Sale of Common Shares
Reuters · 12/11 17:10
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Webull offers Ultragenyx Pharmaceutical Inc stock information, including NASDAQ: RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.